From the Chromadex earnings call earlier this month:

CEO Rob Fried:

“…So people who are getting NAD IV or even taking NAD, there is an increase, a small increase in their NAD levels.

But the reason for that is because the NAD molecule is breaking down in the bloodstream into smaller molecules.

And one of the smaller molecules it breaks down into is NR.

And then the NR will be – a small amount of NR will then get taken up into the cell.

But they have to go through quite a process to get it there, which creates a lot of agony and inflammation and other issues.

The other issue about – you see a lot of companies emerging talking about NAD levels in the blood.

And we do, in fact, have a kit that we sell to some people who are constantly asking what my NAD levels.

The problem with measuring your NAD levels in the blood is it really isn’t a great indicator of much. You really want to measure your NAD levels in the cells, in the tissue cells.

But even then, you really want to measure them in the damaged tissue cells, which is very difficult to do in humans.

It’s kind of easy to do in rats and mice.

But unless you’re going to do a biopsy, it’s quite difficult to do in a human.

You can do it in the brain with an MRI. You can measure NAD levels in the brain with MRIs, and we’ve done that. And it’s one of the reasons we’re so aggressive with these neurodegenerative diseases like ataxia and Parkinson’s and Alzheimer’s, because they’re all neurodegenerative diseases, and we can measure NAD levels, as well as the therapeutic benefits of taking Tru Niagen.

So, we could conceivably partner with some of these clinics that are out there in the NAD business or selling NAD or doing NAD IV.

But we’re not very confident in the quality of the data that it would deliver.

So it might be more of a marketing exercise than a science exercise.

Full transcript at Seeking Alpha

Related:

FOLLOW us on Twitter @RaisingNAD